Egyptian International Pharmaceutical Investments (CAI:PHAR) Cash Flow for Dividends: E£-547 Mil (TTM As of Mar. 2026)


CAI:PHAR Egyptian International Pharmaceutical Investments CAI:PHAR
69 GF Score
Price E£88.21
GF Value E£59.72
Valuation Significantly Overvalued
! 12 Warning Signs
View Full Analysis

What is Egyptian International Pharmaceutical Investments Cash Flow for Dividends?

Egyptian International Pharmaceutical Investments CAI:PHAR +0.94% 69 Cash Flow for Dividends is E£-547 Mil as of Mar. 2026. GuruFocus rates CAI:PHAR with a GF Score™ of 69/100 and a GF Value™ of E£59.72 (Significantly Overvalued). The stock has 12 warning signs investors should review.

Egyptian International Pharmaceutical Investments's cash flow for dividends for the three months ended in Mar. 2026 was E£0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was E£-547 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Egyptian International Pharmaceutical Investments's quarterly payment of dividends declined from Jun. 2025 (E£-323 Mil) to Sep. 2025 (E£-223 Mil) and declined from Sep. 2025 (E£-223 Mil) to Mar. 2026 (E£0 Mil).

Egyptian International Pharmaceutical Investments's annual payment of dividends declined from Dec. 2022 (E£-393 Mil) to Dec. 2023 (E£-310 Mil) but then increased from Dec. 2023 (E£-310 Mil) to Dec. 2024 (E£-434 Mil).

Egyptian International Pharmaceutical Investments Cash Flow for Dividends Related Terms

Egyptian International Pharmaceutical Investments Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Egyptian International Pharmaceutical Investments's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egyptian International Pharmaceutical Investments Cash Flow for Dividends Chart

Egyptian International Pharmaceutical Investments Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -383.57 -393.14 -309.76 -434.01

Egyptian International Pharmaceutical Investments Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.55 -63.21 -323.34 -223.49 0.00
CAI:PHAR
69GF Score
Egyptian International Pharmaceutical Investments CAI:PHAR
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Egyptian International Pharmaceutical Investments Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£-547 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of E£-547 Mil mean?
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a Cash Flow for Dividends of E£-547 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Egyptian International Pharmaceutical Investments and its competitors.
Is Egyptian International Pharmaceutical Investments' Cash Flow for Dividends too high?
Egyptian International Pharmaceutical Investments' current Cash Flow for Dividends is E£-547 Mil. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' Cash Flow for Dividends compare to ZTS and UTHR?
Egyptian International Pharmaceutical Investments' Cash Flow for Dividends of E£-547 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Drug Manufacturers company?
A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Egyptian International Pharmaceutical Investments and its competitors. Egyptian International Pharmaceutical Investments's current Cash Flow for Dividends is E£-547 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.72, compared to a current price of E£88.21 — trading 47.7% above its estimated fair value. The current Cash Flow for Dividends is E£-547 Mil. Egyptian International Pharmaceutical Investments' overall GF Score™ is 69/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current Cash Flow for Dividends is E£-547 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued. The current stock price of E£88.21 is trading 47.7% above its estimated GF Value™ of E£59.72. GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.

Key valuation signals for CAI:PHAR:

  • Cash Flow for Dividends: E£-547 Mil
  • GF Value™: E£59.72 vs. price of E£88.21 (47.7% above fair value)
  • GF Score™: 69/100 with 12 warning signs

No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Egyptian International Pharmaceutical Investments Business Description

Address 1st Industrial Zone B1, EIPICO, Tenth of Ramadan City, EGY
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
69GF Score

Get the complete analysis for CAI:PHAR

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£88.21
Price
E£59.72
GF Value